Zacks Investment Research upgraded shares of Fibrocell Science Inc (NASDAQ:FCSC) from a sell rating to a hold rating in a research report report published on Friday morning.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
A number of other analysts have also recently issued reports on the company. HC Wainwright reissued a buy rating and issued a $5.70 target price on shares of Fibrocell Science in a research report on Friday. Canaccord Genuity reissued a buy rating and issued a $7.00 target price (up from $3.00) on shares of Fibrocell Science in a research report on Monday, September 11th. Finally, ValuEngine cut Fibrocell Science from a sell rating to a strong sell rating in a research report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Fibrocell Science presently has a consensus rating of Hold and an average price target of $4.74.
Shares of Fibrocell Science (NASDAQ FCSC) opened at 3.38 on Friday. The company’s 50 day moving average price is $2.92 and its 200-day moving average price is $2.60. The firm’s market cap is $49.74 million. Fibrocell Science has a 12-month low of $1.57 and a 12-month high of $4.64.
Fibrocell Science (NASDAQ:FCSC) last announced its earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%. On average, equities research analysts anticipate that Fibrocell Science will post ($2.17) EPS for the current year.
An institutional investor recently raised its position in Fibrocell Science stock. Parametric Portfolio Associates LLC boosted its stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,259 shares of the company’s stock after acquiring an additional 35,000 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.33% of Fibrocell Science worth $194,000 as of its most recent filing with the Securities and Exchange Commission. 54.70% of the stock is owned by institutional investors and hedge funds.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.